UY37331A - Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 - Google Patents

Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2

Info

Publication number
UY37331A
UY37331A UY0001037331A UY37331A UY37331A UY 37331 A UY37331 A UY 37331A UY 0001037331 A UY0001037331 A UY 0001037331A UY 37331 A UY37331 A UY 37331A UY 37331 A UY37331 A UY 37331A
Authority
UY
Uruguay
Prior art keywords
aminopiridine
alk
derivatives
selective inhibitors
compound
Prior art date
Application number
UY0001037331A
Other languages
English (en)
Inventor
Luca Arista
Patrick Dillon Michael
Lattmann René
Dimitrios Lizos
Johannes Stiefl Nikolaus
Peggy Usselmann
Sven Weiler
Thomas Ullrich
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY37331A publication Critical patent/UY37331A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se relaciona con un compuesto de la fórmula (I) en forma libre o en forma de sal farmacéuticamente aceptable a composiciones farmacéuticas que comprenden dicho compuesto y al uso de dicho compuesto en el tratamiento de la osificación heterotópica y fibrodisplasia osificante progresiva.
UY0001037331A 2016-07-20 2017-07-19 Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 UY37331A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662364620P 2016-07-20 2016-07-20

Publications (1)

Publication Number Publication Date
UY37331A true UY37331A (es) 2018-02-28

Family

ID=60991950

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037331A UY37331A (es) 2016-07-20 2017-07-19 Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2

Country Status (26)

Country Link
US (3) US10710980B2 (es)
EP (2) EP3487851B1 (es)
JP (3) JP7030776B2 (es)
KR (6) KR102359707B1 (es)
CN (2) CN114014844A (es)
AR (1) AR109108A1 (es)
AU (5) AU2017298187B2 (es)
BR (1) BR112019000941A2 (es)
CA (1) CA3030332A1 (es)
CY (1) CY1124967T1 (es)
DK (2) DK3487851T3 (es)
EA (2) EA202190285A1 (es)
ES (1) ES2902521T3 (es)
FI (1) FI3971177T3 (es)
HR (1) HRP20211868T1 (es)
HU (1) HUE057328T2 (es)
LT (2) LT3971177T (es)
MX (2) MX2019000837A (es)
PL (1) PL3487851T3 (es)
PT (2) PT3487851T (es)
RS (1) RS62819B1 (es)
RU (1) RU2747318C2 (es)
SI (1) SI3487851T1 (es)
TW (3) TWI712598B (es)
UY (1) UY37331A (es)
WO (1) WO2018014829A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI712598B (zh) * 2016-07-20 2020-12-11 瑞士商諾華公司 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
PE20230251A1 (es) * 2019-11-22 2023-02-07 Incyte Corp Terapia de combinacion que comprende un inhibidor de alk2 y un inhibidor de jak2
CN111170893B (zh) * 2020-01-19 2022-04-26 郑州依米花手性药物研究有限公司 Lefamulin的中间体化合物及其在Lefamulin制备中的应用
JP2023530316A (ja) 2020-06-16 2023-07-14 インサイト・コーポレイション 貧血の治療のためのａｌｋ２阻害剤
WO2023198114A1 (zh) * 2022-04-13 2023-10-19 杭州邦顺制药有限公司 Alk2激酶抑制剂

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077290A (en) 1990-10-11 1991-12-31 Merck & Co., Inc. Morpholine derivatives compositions and use
AU683431B2 (en) 1992-11-17 1997-11-13 Ludwig Institute For Cancer Research Activin receptor-like kinases, proteins having serine/ threonine kinase domains and their use
TW530054B (en) 1997-09-24 2003-05-01 Duphar Int Res New piperazine and piperidine compounds
SE0102439D0 (sv) 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
US6914058B2 (en) * 2002-01-18 2005-07-05 Dr. Reddy's Laboratories, Limited Antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
JP4901102B2 (ja) 2002-05-03 2012-03-21 エクセリクシス， インク． プロテインキナーゼモジュレーターおよびその使用方法
AU2003249369A1 (en) 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain amino-substituted monocycles as kinase modulators
US20040067985A1 (en) 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
SE0203753D0 (sv) 2002-12-17 2002-12-17 Astrazeneca Ab New compounds
FR2850652B1 (fr) * 2003-01-31 2008-05-30 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
AU2004230519A1 (en) 2003-04-11 2004-10-28 Sgx Pharmaceuticals, Inc. Compound libraries and methods for drug discovery
EP1758862A1 (en) 2004-05-27 2007-03-07 Pfizer Limited Aminopyridine derivatives as selective dopamine d3 agonists
SA05260265A (ar) 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
AU2006234627C1 (en) 2005-04-08 2009-11-26 Eisai R & D Management Co., Ltd. Therapeutic agent for dyskinesia
WO2007011760A2 (en) 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
PE20071241A1 (es) 2006-01-17 2008-01-14 Schering Corp Compuestos derivados de hidantoina para el tratamiento de trastornos inflamatorios
WO2007123896A2 (en) 2006-04-18 2007-11-01 The Trustees Of The University Of Pennsylvania Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop)
US20080021024A1 (en) 2006-06-29 2008-01-24 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
JP2010502220A (ja) 2006-09-05 2010-01-28 メダレックス インコーポレーティッド 骨形態形成タンパク質およびその受容体に対する抗体ならびにその使用方法
US20100093760A1 (en) 2006-09-12 2010-04-15 The General Hospital Corporation Methods for identifying compounds that modulate cell signaling and methods employing such compounds
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
WO2009114180A1 (en) 2008-03-13 2009-09-17 The General Hospital Corporation Inhibitors of the bmp signaling pathway
JP2011524917A (ja) 2008-06-20 2011-09-08 メタボレックス， インコーポレイテッド アリールｇｐｒ１１９作動薬およびその使用
EP3320913B1 (en) 2010-08-20 2019-11-27 Wyeth LLC Designer osteogenic proteins
WO2012077031A1 (en) 2010-12-06 2012-06-14 Piramal Life Sciences Limited Substituted imidazoquinoline derivatives
WO2012087938A1 (en) 2010-12-20 2012-06-28 Glaxosmithkline Llc Quinazolinone derivatives as antiviral agents
EP2655334B1 (en) 2010-12-22 2018-10-03 Eutropics Pharmaceuticals, Inc. Compositions and methods useful for treating diseases
RS58015B1 (sr) 2011-05-23 2019-02-28 Merck Patent Gmbh Piridin- i pirazin derivati
BR112014005286B1 (pt) 2011-09-09 2022-08-23 Lantheus Medical Imaging, Inc Compostos de um primeiro e um segundo agente de imageamento para determinar incompatibilidade de inervação e perfusão na parte do indivíduo
ES2660051T3 (es) * 2012-09-28 2018-03-20 Vanderbilt University Compuestos heterocíclicos condensados como inhibidores selectivos de BMP
US20160115167A1 (en) * 2013-03-04 2016-04-28 The Brigham And Women's Hospital, Inc. Bmp inhibitors and methods of use thereof
JP6542192B2 (ja) 2013-03-14 2019-07-10 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． Ｂｍｐ阻害剤およびその使用方法
CN105308033B (zh) * 2013-03-14 2018-08-24 特雷罗药物股份有限公司 Jak2和alk2抑制剂及其使用方法
WO2015061247A2 (en) 2013-10-21 2015-04-30 Merck Patent Gmbh Heteroaryl compounds as btk inhibitors and uses thereof
WO2015152183A1 (ja) 2014-03-31 2015-10-08 大日本住友製薬株式会社 進行性骨化性線維異形成症の予防剤及び治療剤
CN107257793A (zh) 2015-01-20 2017-10-17 梅里亚股份有限公司 抗蠕虫化合物、组合物及其使用方法
TWI712598B (zh) * 2016-07-20 2020-12-11 瑞士商諾華公司 胺基吡啶衍生物及其作為選擇性alk-2抑制劑之用途
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation

Also Published As

Publication number Publication date
AU2019246857A1 (en) 2019-10-31
CY1124967T1 (el) 2023-01-05
KR20220143770A (ko) 2022-10-25
JP7253086B2 (ja) 2023-04-05
RU2021111037A3 (es) 2022-02-10
US10947218B2 (en) 2021-03-16
KR102454129B1 (ko) 2022-10-14
TWI806385B (zh) 2023-06-21
LT3487851T (lt) 2021-12-27
AU2021201424A1 (en) 2021-03-25
US20190161474A1 (en) 2019-05-30
KR20240074904A (ko) 2024-05-28
HUE057328T2 (hu) 2022-05-28
PL3487851T3 (pl) 2022-04-11
WO2018014829A1 (en) 2018-01-25
EP3487851A1 (en) 2019-05-29
MX2019000837A (es) 2019-07-04
US20210155606A1 (en) 2021-05-27
EP3487851B1 (en) 2021-10-20
JP2022078137A (ja) 2022-05-24
AU2017298187B2 (en) 2019-11-14
AU2021201424C1 (en) 2023-02-02
KR20210094138A (ko) 2021-07-28
EP3971177A1 (en) 2022-03-23
AU2017298187A1 (en) 2018-12-20
RU2021111037A (ru) 2021-05-13
AU2019246857B2 (en) 2020-12-24
EP3971177B1 (en) 2024-06-26
KR20230117248A (ko) 2023-08-07
EA202190285A1 (ru) 2021-08-31
KR102667331B1 (ko) 2024-05-21
AU2023200265B2 (en) 2024-08-15
JP2019521167A (ja) 2019-07-25
AR109108A1 (es) 2018-10-31
DK3487851T3 (da) 2021-12-20
RU2747318C2 (ru) 2021-05-04
HRP20211868T1 (hr) 2022-03-04
SI3487851T1 (sl) 2022-03-31
KR102281550B1 (ko) 2021-07-27
JP7030776B2 (ja) 2022-03-07
BR112019000941A2 (pt) 2019-04-30
EP3487851A4 (en) 2019-12-25
JP2023089012A (ja) 2023-06-27
PT3971177T (pt) 2024-07-30
DK3971177T3 (da) 2024-07-15
AU2023200265A1 (en) 2023-02-16
RU2019104609A3 (es) 2020-09-30
EA201990343A1 (ru) 2019-06-28
CN109641871B (zh) 2021-10-22
TW201805277A (zh) 2018-02-16
ES2902521T3 (es) 2022-03-28
KR102559539B1 (ko) 2023-07-26
TWI755255B (zh) 2022-02-11
CN109641871A (zh) 2019-04-16
AU2021201424B2 (en) 2022-10-20
LT3971177T (lt) 2024-08-26
KR102359707B1 (ko) 2022-02-09
US20200299265A1 (en) 2020-09-24
TW202336011A (zh) 2023-09-16
RU2019104609A (ru) 2020-08-20
CA3030332A1 (en) 2018-01-25
MX2021014852A (es) 2022-01-18
KR20190026917A (ko) 2019-03-13
TWI712598B (zh) 2020-12-11
TW202220969A (zh) 2022-06-01
PT3487851T (pt) 2022-01-07
TW202134228A (zh) 2021-09-16
AU2024205058A1 (en) 2024-08-15
RS62819B1 (sr) 2022-02-28
KR20220021023A (ko) 2022-02-21
US10710980B2 (en) 2020-07-14
EA037520B1 (ru) 2021-04-07
FI3971177T3 (fi) 2024-07-30
CN114014844A (zh) 2022-02-08

Similar Documents

Publication Publication Date Title
UY37331A (es) Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2
CL2018000952A1 (es) Compuestos útiles como inmunomoduladores
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
CL2019003669A1 (es) Inhibidores de quinasa alk2 que contienen imidazol.
CY1119767T1 (el) Παραγωγα πιπεριδινυλικης ινδολης και η χρηση τους ως αναστολεις του παραγοντα β του συμπληρωματος
MX2020004932A (es) Compuestos utiles para inhibir a cdk7.
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
BR112018003026A2 (pt) composições compreendendo um inibidor de pi3k e um inibidor de hdac
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
CO7180201A2 (es) Inhibidores de neprilisina
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
UY36330A (es) Compuestos inhibidores de quinasa de unión a tank
CL2016001283A1 (es) Derivado de urea o sal farmacológicamente aceptable del mismo
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
GT201500235A (es) Estra -1,3,5 (10) , 16- tetraeno -3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1c3)
BR112012018955A2 (pt) combinação para administração simultânea, separada ou sequencial e ligante sigma ou um sal, isômero, pró-droga ou solvato farmaceuticamente aceitável do mesmo
CL2017001720A1 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos.
CL2019000487A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana.
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
CY1119540T1 (el) Υποκατασταθεντα απο γλυκοπυρανοσυλιο παραγωγα ινδολο-ουριας και η χρηση τους ως αναστολεις sglt
BR112016024236A2 (pt) composições farmacêuticas compreendendo agentes antibacterianos
BR112019021330A2 (pt) Métodos e compostos terapêuticos.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20230626